Fostamatinib is a pro-drug of a Syk inhibitor R406 initially developed by Rigel Pharmaceuticals, but then in-licensed by AstraZeneca. It reached phase III of clinical trials for such diseases as Rheumatoid Arthritis and Immune Thrombocytopenic Purpura, however, AstraZeneca decided not to proceed with regulatory filings and return the rights to the compound to Rigel Pharmaceuticals. In 2018 the drug was approved by the FDA for treatment of chronic immune thrombocytopenia. Fostamatinib is being developed for Autoimmune Hemolytic Anemia (phase II), graft versus host disease (phase I) and ovarian cancer (phase I).

Emtricitabine was discovered by Emory researchers Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi and Dr. Woo-Baeg Choi and licensed to Triangle Pharmaceuticals by Emory University in 1996. Triangle was acquired by Gilead in 2003. Emtricitabine, marketed by Gilead as Emtriva, was first approved by the U.S. Food and Drug Administration in July 2003 for the treatment of HIV infection in combination with other antiretroviral agents. Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination.

Pinacyanol iodide is a fluorescent cationic cyanine dye used to stain biological specimens. It is the obstetric diagnostic aid. The mechanism of tracing with pinacyanol iodide dyes is based on their lipid solubility. Pinacyanol iodide dyes are more efficacious than classical tracing methodologies especially during early stages of development and consequently have been used to reveal the spatiotemporal patterns of axonal development in different species. The unique properties of the pinacyanol iodide dye tracing method have opened up new avenues for tracing connections in human postmortem specimens. Pinacyanol iodide dye tracing is incompatible with alcohol fixation and paraffin embedding of tissue.

Methylene di-t-butylcresol (GERI-BP002-A) is a hindered phenolic antioxidant and thermal stabilizer providing effective stabilization in adhesives, ABS, polyolefins, and other substrates. GERI-BP002-A is a novel inhibitor of SOAT (Acyl-CoA Cholesterol Acyltransferase (ACAT)) which is produced by Aspergillus fumigatus F93. GERI-BP002-A also exhibits antioxidant activity.